Crystal Adam
- SEC CIK
- 0001825445
In the past year, 11 open-market sale filings worth $6.33M and no purchases.
Current role at each company
- TNGX Tango Therapeutics, Inc.President, R&Das of Sep 3, 2026
- CCCC C4 Therapeutics, Inc.Chief Medical Officeras of Feb 1, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $6.33M
- 11 filings
- Net
- −$6.33M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Crystal Adam as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
TNGX Tango Therapeutics, Inc.
President, R&D14 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 (view filing)4:01 PM ET | Sep 1 | 2 days | Crystal AdamPresident, R&D | SSale | −27.0K | $22.37 | −$603.9K | −18.9%115.7K after | 10b5-1 |
| Aug 5, 2026 (view filing)4:01 PM ET | Aug 3 | 2 days | Crystal AdamPresident, R&D | SSale | −27.0K | $27.24 | −$735.5K | −18.9%115.7K after | 2 lots10b5-1 |
| Jul 2, 2026 (view filing)7:23 PM ET | Jul 1 | 1 day | Crystal AdamPresident, R&D | SSale | −27.0K | $29.59 | −$798.9K | −18.9%115.7K after | 2 lots10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Crystal AdamPresident, R&D | SSale | −27.0K | $22.88 | −$617.6K | −18.9%115.7K after | 2 lots10b5-1 |
| May 5, 2026 (view filing) | May 1 | 4 days | Crystal AdamPresident, R&D | SSale | −27.0K | $21.22 | −$573.0K | −18.9%115.7K after | 2 lots10b5-1 |
| Apr 16, 2026 (view filing) | Apr 15 | 1 day | Crystal AdamPresident, R&D | SSale | −38.5K | $25.00 | −$961.5K | −25.5%112.6K after | 10b5-1 |
| Apr 2, 2026 (view filing) | Apr 1 | 1 day | Crystal AdamPresident, R&D | SSale | −27.0K | $21.20 | −$572.4K | −19.3%112.6K after | 10b5-1 |
| Mar 27, 2026 (view filing) | Mar 25 | 2 days | Crystal AdamPresident, R&D | SSale | −12.0K | $20.11 | −$241.3K | −9.6%112.6K after | 10b5-1 |
| Mar 9, 2026 (view filing) | Mar 5 | 4 days | Crystal AdamPresident, R&D | SSale | −20.3K | $15.00 | −$303.8K | −15.2%112.6K after | 10b5-1 |
| Feb 27, 2026 (view filing) | Feb 25 | 2 days | Crystal AdamPresident, R&D | SSale | −54.3K | $12.77 | −$694.0K | −29.0%132.9K after | 10b5-1 |
CCCC C4 Therapeutics, Inc.
Chief Medical Officer4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2022 (view filing) | Jan 4 | 1 day | Crystal AdamChief Medical Officer | SSale | −15.0K | $31.67 | −$475.0K | −50.0%15.0K after | 2 lots |
| Oct 5, 2021 (view filing) | Oct 1 | 4 days | Crystal AdamChief Medical Officer | SSale | −15.0K | $45.43 | −$681.4K | −100.0%0 after | 3 lots |
| Aug 2, 2021 (view filing) | Jul 29 | 4 days | Crystal AdamChief Medical Officer | SSale | −15.0K | $45.00 | −$675.0K | −100.0%0 after | |
| Jul 6, 2021 (view filing) | Jul 1 | 5 days | Crystal AdamChief Medical Officer | SSale | −15.0K | $37.98 | −$569.7K | −100.0%0 after | 2 lots |